Tsukuba, Japan

Takaaki Harada

This inventor holds 1 USPTO granted patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takaaki Harada. Retrieved from https://idiyas.com/inventor/takaaki-harada-fp6jpkya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takaaki Harada: Innovator in Pentacyclic Heterocycles

Introduction

Takaaki Harada is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on pentacyclic heterocycles. His research and inventions have the potential to impact various therapeutic areas.

Latest Patents

Takaaki Harada holds one patent related to his work on pentacyclic heterocycles. The patent provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof. This invention showcases his expertise in developing novel chemical compounds that may have important applications in medicine.

Career Highlights

Harada is currently employed at Eisai R&D Management Co., Ltd., where he continues to advance his research in pharmaceutical sciences. His work at Eisai has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to innovation.

Collaborations

Some of Takaaki Harada's coworkers include Yoshiaki Ohashi and Yoshihiko Norimine. Their collaborative efforts contribute to the dynamic research environment at Eisai, fostering innovation and the development of new therapeutic solutions.

Conclusion

Takaaki Harada is a distinguished inventor whose work on pentacyclic heterocycles exemplifies the intersection of chemistry and medicine. His contributions to the field are significant and reflect his commitment to advancing pharmaceutical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…